Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Oseltamivir"" wg kryterium: Temat


Tytuł:
Predicting complex kidney drug handling using a physiologically-based pharmacokinetic model informed by biomarker-estimated secretory clearance and blood flow.
Autorzy:
Granda ML; Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.; Kidney Research Institute, Seattle, Washington, USA.
Huang W; Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.; Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Yeung CK; Kidney Research Institute, Seattle, Washington, USA.; Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Isoherranen N; Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Kestenbaum B; Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.; Kidney Research Institute, Seattle, Washington, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13678. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Oseltamivir*
Kidney*
Humans ; Adult ; Middle Aged ; Aged ; Kidney Function Tests ; Glomerular Filtration Rate/physiology ; Biomarkers ; Tenofovir
Czasopismo naukowe
Tytuł:
Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design.
Autorzy:
El-Shorbagy HI; Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. .
Mohamed MA; Pharmaceutical Chemistry Department, Egyptian Drug Authority (EDA), Cairo, Egypt.
El-Gindy A; Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Hadad GM; Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Belal F; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Apr 04; Vol. 13 (1), pp. 5466. Date of Electronic Publication: 2023 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Oseltamivir*
COVID-19*
Humans ; Chromatography, High Pressure Liquid/methods ; Dexamethasone ; Phosphates
Czasopismo naukowe
Tytuł:
A novel N -heterocycles substituted oseltamivir derivatives as potent inhibitors of influenza virus neuraminidase: discovery, synthesis and biological evaluation.
Autorzy:
Zhang J; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Liu C; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.; Suzhou Research Institute of Shandong University, Suzhou, Jiangsu, P.R. China.
Jia R; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Zhang X; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Zhang J; Institute of Medical Sciences, The Second Hospital, Shandong University, Jinan, Shandong, P.R. China.
Bertagnin C; Department of Molecular Medicine, University of Padova, Padova, Italy.
Bonomini A; Department of Molecular Medicine, University of Padova, Padova, Italy.
Guizzo L; Department of Molecular Medicine, University of Padova, Padova, Italy.
Jiang Y; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Jia H; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Jia S; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.
Ma X; Institute of Poultry Science, Shandong Academy of Agricultural Sciences, Jinan, Shandong, P.R. China.
Loregian A; Department of Molecular Medicine, University of Padova, Padova, Italy.
Huang B; Institute of Poultry Science, Shandong Academy of Agricultural Sciences, Jinan, Shandong, P.R. China.
Zhan P; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.; China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan, Shandong, PR China.
Liu X; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.; China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan, Shandong, PR China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2277135. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza A Virus, H5N1 Subtype*/metabolism
Influenza A Virus, H1N1 Subtype*
Oseltamivir/pharmacology ; Oseltamivir/chemistry ; Neuraminidase ; Molecular Docking Simulation ; Influenza A Virus, H3N2 Subtype/metabolism ; Glycoside Hydrolases
Czasopismo naukowe
Tytuł:
Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses.
Autorzy:
Fukao K; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Noshi T; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Shano S; Shionogi TechnoAdvance Research, Co., Ltd., Osaka 561-0825, Japan.
Baba K; Shionogi TechnoAdvance Research, Co., Ltd., Osaka 561-0825, Japan.
Sato K; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Sakuramoto M; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Kitade N; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Tanioka H; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Kusakabe S; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Shishido T; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Nov 16; Vol. 15 (11). Date of Electronic Publication: 2023 Nov 16.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*/drug therapy
Influenza, Human*/prevention & control
Herpesvirus 1, Cercopithecine*
Influenza A Virus, H1N1 Subtype*
Thiepins*/pharmacology
Thiepins*/therapeutic use
Humans ; Animals ; Mice ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Oxazines/therapeutic use ; Pyridines/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Mice, Inbred BALB C ; Phosphates
Czasopismo naukowe
Tytuł:
Characterization of two excipient interaction degradation products in oseltamivir phosphate powder for oral suspension by MS and NMR.
Autorzy:
Yao B; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Guo Y; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Xie Q; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Jiang M; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Sun F; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Zhao Y; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.
Tan G; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.
Sun J; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Huang F; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Song X; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
You J; Dongguan HEC Generic Drug R&D Co., Ltd, Dongguan, China.; State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan, China.
Pokaż więcej
Źródło:
Journal of mass spectrometry : JMS [J Mass Spectrom] 2022 Dec; Vol. 57 (12), pp. e4899.
Typ publikacji:
Journal Article
MeSH Terms:
Oseltamivir*/chemistry
Excipients*/chemistry
Humans ; Child ; Powders ; Chromatography, Liquid ; Tandem Mass Spectrometry ; Drug Contamination ; Phosphates ; Citrates
Czasopismo naukowe
Tytuł:
Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication.
Autorzy:
Murray J; Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Martin DE; TrippBio, Inc., Jacksonville, FL 32256, USA.
Sancilio FD; TrippBio, Inc., Jacksonville, FL 32256, USA.
Tripp RA; Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.; TrippBio, Inc., Jacksonville, FL 32256, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Nov 30; Vol. 15 (12). Date of Electronic Publication: 2023 Nov 30.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*
Influenza Vaccines*/therapeutic use
Humans ; Animals ; Mice ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Probenecid/pharmacology ; Probenecid/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Enzyme Inhibitors/pharmacology ; Virus Replication ; Neuraminidase ; Drug Resistance, Viral
Czasopismo naukowe
Tytuł:
Online searches of children's oseltamivir in public primary and specialized care: Detecting influenza outbreaks in Finland using dedicated databases for health care professionals.
Autorzy:
Mukka M; University of Helsinki, Helsinki, Finland.
Pesälä S; University of Helsinki, Helsinki, Finland.; Epidemiological Operations Unit, City of Helsinki, Helsinki, Finland.
Juutinen A; Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
Virtanen MJ; Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
Mustonen P; Duodecim Medical Publications Ltd, Helsinki, Finland.
Kaila M; Clinicum, University of Helsinki, Helsinki, Finland.
Helve O; Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.; Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Aug 05; Vol. 17 (8), pp. e0272040. Date of Electronic Publication: 2022 Aug 05 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*/diagnosis
Influenza, Human*/drug therapy
Influenza, Human*/epidemiology
Oseltamivir*/therapeutic use
Antiviral Agents/therapeutic use ; Child ; Child, Preschool ; Disease Outbreaks ; Finland/epidemiology ; Health Personnel ; Humans
Czasopismo naukowe
Tytuł:
Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs.
Autorzy:
Tao J; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Wang H; Department of Respiratory diseases of Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Wang W; Department of Respiratory diseases of Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Mi N; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Zhang W; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Wen Q; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Ouyang J; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Liang X; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Chen M; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Guo W; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Li G; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Liu J; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Zhao H; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Wang X; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Li X; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Feng S; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Liu X; Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Institute of Aging Research, Guangdong Medical University, Dongguan, Guangdong Province, China.
He Z; Department of Sino US joint Cancer Institute of Guangdong Medical University, Dongguan, Guangdong Province, China.
Zhao Z; Department of Microbiology and Immunology of Basical Medicine of Guangdong Medical University, Dongguan, Guangdong Province, China.
Pokaż więcej
Źródło:
PLoS computational biology [PLoS Comput Biol] 2022 Jul 28; Vol. 18 (7), pp. e1010343. Date of Electronic Publication: 2022 Jul 28 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Influenza, Human*
Oseltamivir*/chemistry
Oseltamivir*/metabolism
Oseltamivir*/pharmacology
Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Drug Resistance, Viral/genetics ; Enzyme Inhibitors/chemistry ; Humans ; Neuraminidase/chemistry
Czasopismo naukowe
Tytuł:
Oseltamivir induces favorable response on oxidative damage in the brain of rats treated with Bezafibrate.
Autorzy:
Calderón Guzmán D; Laboratory of Neuroscience, National Institute of Pediatrics (NIP), Mexico City, Mexico.
Osnaya Brizuela N; Laboratory of Neuroscience, National Institute of Pediatrics (NIP), Mexico City, Mexico.
Ortiz Herrera M; Laboratory of Experimental Bacteriology, NIP, Mexico City, Mexico.
Juárez Olguín H; Laboratory of Pharmacology, NIP and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Veloz Corona Q; Laboratory of Pharmacology, NIP and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Sanchez Reyes L; Laboratory of Pharmacology, NIP and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Valenzuela Peraza A; Laboratory of Neuroscience, National Institute of Pediatrics (NIP), Mexico City, Mexico.
Barragán Mejía G; Laboratory of Neuroscience, National Institute of Pediatrics (NIP), Mexico City, Mexico.
Pokaż więcej
Źródło:
The International journal of neuroscience [Int J Neurosci] 2022 Jun; Vol. 132 (6), pp. 574-581. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji:
Journal Article
MeSH Terms:
Dopamine*
Oseltamivir*/pharmacology
Adenosine Triphosphatases/metabolism ; Animals ; Bezafibrate/pharmacology ; Brain/metabolism ; Glutathione/metabolism ; Hydrogen Peroxide/pharmacology ; Hydroxyindoleacetic Acid/pharmacology ; Lipid Peroxidation ; Male ; Oxidative Stress ; Rats ; Rats, Wistar
Czasopismo naukowe
Tytuł:
Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling.
Autorzy:
Medeiros JJS; Coordenação de Desenvolvimento Tecnológico, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Costa TM; Laboratório de Tecnologia Farmacêutica, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Carmo MP; Laboratório de Tecnologia Farmacêutica, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Nascimento DD; Laboratório de Desenvolvimento e Validação Analítica, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Lauro ENC; Departamento de Ciências Farmacêuticas, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Diadema, Brazil.
Oliveira CA; Laboratório de Desenvolvimento e Validação Analítica, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Duque MD; Departamento de Ciências Farmacêuticas, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Diadema, Brazil.
Prado LD; Laboratório de Desenvolvimento e Validação Analítica, Instituto de Tecnologia em Farmacos, Farmanguinhos, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło:
Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2022 Apr; Vol. 48 (4), pp. 146-157. Date of Electronic Publication: 2022 Jul 24.
Typ publikacji:
Journal Article
MeSH Terms:
Models, Biological*
Oseltamivir*
Capsules ; Drug Development ; Humans ; Phosphates ; Therapeutic Equivalency ; Water
Czasopismo naukowe
Tytuł:
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses.
Autorzy:
Kuroda T; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Fukao K; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Yoshida S; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Oka R; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Baba K; Shionogi TechnoAdvance Research, Co., Ltd., Osaka 561-0825, Japan.
Ando Y; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Taniguchi K; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Noshi T; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Shishido T; Shionogi & Co., Ltd., Osaka 561-0825, Japan.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 May 11; Vol. 15 (5). Date of Electronic Publication: 2023 May 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Influenza A virus*
Influenza A Virus, H1N1 Subtype*
Thiepins*/pharmacology
Thiepins*/therapeutic use
Influenza, Human*
Humans ; Animals ; Mice ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Oxazines/pharmacology ; Pyridines/pharmacology ; Influenza A Virus, H3N2 Subtype ; Drug Resistance, Viral ; Nucleotidyltransferases ; Phosphates
Czasopismo naukowe
Tytuł:
Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.
Autorzy:
Bai X; Emergency Department, Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, 050051, Hebei, China.
Xi S; Hebei Chest Hospital, Shijiazhuang, Hebei, China.
Chen G; Chengde Central Hospital, Chengde, Hebei, China.
Fan X; Handan Central Hospital, Handan, Hebei, China.
Wang K; The Sixth People's Hospital of Hengshui, Hengshui, Hebei, China.
Li Y; Cangzhou Central Hospital, Cangzhou, Hebei, China.
Zhao Y; Qinhuangdao Traditional Chinese Medicine Hospital, Qinhuangdao, Hebei, China.
Wang W; Harrison International Peace Hospital, Hengshui, Hebei, China.
Tian Y; Emergency Department, Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, 050051, Hebei, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Sep 06; Vol. 23 (1), pp. 585. Date of Electronic Publication: 2023 Sep 06.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Influenza, Human*/drug therapy
Humans ; Capsules ; Oseltamivir ; Fever/drug therapy ; Fever/etiology ; Nausea ; Tablets ; Phosphates
Czasopismo naukowe
Tytuł:
Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis.
Autorzy:
Harbin NJ; Antibiotic Center for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
Rystedt K; Research, Education, Development and Innovation, Primary Health Care, Region Västra Götaland, Sweden.; General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Närhälsan Stenstorp vårdcentral, Stenstorp, Sweden.
Lindbaek M; Antibiotic Center for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
Radzeviciene R; Mano Seimos gydytojas, Klaipeda, Lithuania.
Westin J; Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Gunnarsson R; Research, Education, Development and Innovation, Primary Health Care, Region Västra Götaland, Sweden.; General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Butler CC; Department of Primary Care Health Services, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK.
van der Velden AW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Verheij TJ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Sundvall PD; Research, Education, Development and Innovation, Primary Health Care, Region Västra Götaland, Sweden.; General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Pokaż więcej
Źródło:
Scandinavian journal of primary health care [Scand J Prim Health Care] 2021 Dec; Vol. 39 (4), pp. 527-532. Date of Electronic Publication: 2021 Dec 01.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Influenza, Human*/drug therapy
Oseltamivir*/therapeutic use
Antiviral Agents/therapeutic use ; C-Reactive Protein ; Humans ; Primary Health Care
Czasopismo naukowe
Tytuł:
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.
Autorzy:
Ishiguro N; Division of Infection Control, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan. .
Ito YM; Department of Statistical Data Science, The Institute of Statistical Mathematics, 10-3 Midori-cho, Tachikawa, Tokyo, 190-8562, Japan.
Iwasaki S; Division of Infection Control, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Nagao M; Department of Infection Control and Prevention, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Kyoto, 606-8507, Japan.
Kawamura H; Department of Infection Control and Prevention, Division of Medical and Environmental Safety, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
Kanai S; Division of Infection Control, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Nukui Y; Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Tokuda K; Department of Infection Control and Laboratory Diagnostics, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Miyara T; Infection Control Team, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Igari H; Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.
Yamada K; Department of Infection Control Science, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka, Osaka, 545-8585, Japan.
Chikumi H; Center for Infectious Diseases, Tottori University Hospital, 36-1 Nishi-cho, Yonago, Tottori, 683-8504, Japan.
Sano C; Division of Infection Control, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Koike R; Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Yagi T; Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, Nagoya, 466-8560, Japan.
Murakami N; Center for Regional Medicine, Gifu University School of Medicine, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Pokaż więcej
Corporate Authors:
Japan Infection Prevention, Control Conference for National, Public University Hospitals
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Aug 30; Vol. 21 (1), pp. 887. Date of Electronic Publication: 2021 Aug 30.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Influenza, Human*/drug therapy
Influenza, Human*/prevention & control
Oseltamivir*/therapeutic use
Adult ; Antiviral Agents/therapeutic use ; Child ; Hospitals ; Humans ; Post-Exposure Prophylaxis ; Prospective Studies
Czasopismo naukowe
Tytuł:
Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
Autorzy:
Ishiguro N; Division of Infection Control, Hokkaido University Hospital, Nishi 5, Kita 14, Kita-ku, Sapporo, 060-8648, Japan. .; Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. .
Morioka I; Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.
Nakano T; Department of Pediatrics, Kawasaki Medical School, Okayama, Japan.
Furukawa M; Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan.
Tanaka S; Medical Affairs, Shionogi & Co., Ltd., Tokyo, Japan.
Kinoshita M; Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan.
Manabe A; Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Aug 09; Vol. 21 (1), pp. 777. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antiviral Agents*/therapeutic use
Dibenzothiepins*/therapeutic use
Influenza, Human*/drug therapy
Oseltamivir*/therapeutic use
Adolescent ; Adult ; Child ; Humans ; Morpholines/therapeutic use ; Multicenter Studies as Topic ; Pyridones/therapeutic use ; Randomized Controlled Trials as Topic ; Triazines
Czasopismo naukowe
Tytuł:
Detecting the Neuraminidase R294K Mutation in Avian Influenza A (H7N9) Virus Using Reverse Transcription Droplet Digital PCR Method.
Autorzy:
Lou X; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Yan H; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Su L; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Sun Y; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Wang X; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Gong L; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Chen Y; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Li Z; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Fang Z; Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Mao H; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Chen K; Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Zhang Y; Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Apr 17; Vol. 15 (4). Date of Electronic Publication: 2023 Apr 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Influenza A Virus, H7N9 Subtype*/genetics
Influenza in Birds*
Influenza, Human*
Animals ; Humans ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Neuraminidase/genetics ; Neuraminidase/metabolism ; Reverse Transcription ; Polymerase Chain Reaction ; Mutation ; Birds/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies